Global estimates of cancer prevalence for 27 sites in the adult population in 2008.
Freddie Bray, Jian-Song Ren, Eric Masuyer...
https://pubmed.ncbi.nlm.nih.gov/22752881Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID03978078
Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-02-12
200
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Digestive cancers, including colorectal cancer, are a major health concern worldwide, accounting for 30% of all cancers. This research aims to create a collection of blood samples from patients with metastatic digestive adenocarcinoma who are receiving first or second line treatments. The goal is to study blood biomarkers that could help tailor treatments by predicting and monitoring response in a minimally invasive way. Patients in the study will have blood samples collected before starting treatment and then approximately every two months during treatment until it ends. Alongside this biological collection, standardized clinical data will be recorded in a database. This approach focuses on blood rather than tumor tissue, allowing repeated sampling to better understand tumor dynamics and treatment effects. Participants will be involved throughout their treatment period with regular blood draws and clinical data collection. Researchers will measure clinical and biological risk factors related to metastatic digestive cancer over a study period of up to 54 months. This ongoing monitoring aims to support research projects that improve personalized patient management strategies. The study is sponsored by the Institut du Cancer de Montpellier - Val d'Aurelle.
CONDITIONS
Brief Title
A Clinicobiological Database in Metastatic Digestive Cancers
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Male or female 18 years old or older
- Histological diagnosis of adenocarcinoma in colon, rectum, small intestine, pancreas, stomach, bile duct, or esophagus
- Planned to receive or currently receiving first or second line metastatic chemotherapy and/or targeted therapy
- Signed informed consent form
You will not qualify if you...
- Younger than 18 years old
- Non-adenocarcinoma histology
- Currently receiving specific treatment in first or second metastatic line
- Pregnant or breastfeeding women
- Not affiliated with a social security system
- Unable to have regular follow-up due to psychological, family, social, or geographical reasons
- Enrolled in a Phase I-II therapeutic trial that changes usual management and requires additional blood samples
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Biological Sample Collection
Duration - Up to 54 months
Participants provide blood samples before and during treatment to help identify biomarkers for digestive cancers. Clinical data will also be collected in parallel.
Blood samples collected approximately every other month during treatment
Trial Site Locations
Total: 1 location
1
Institut régional du cancer de Montpellier
Montpellier, Hérault, France, 34298
Actively Recruiting
Loading map...
Research Team
A
Aurore MOUSSION
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S Karapetis, Shirin Khambata-Ford, Derek J Jonker...
https://pubmed.ncbi.nlm.nih.gov/18946061Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena...
https://pubmed.ncbi.nlm.nih.gov/24024839Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova...
https://pubmed.ncbi.nlm.nih.gov/20728210